CAR-T therapy could “alter the treatment paradigm” of multiple sclerosis
Drug Discovery World
JANUARY 5, 2024
KYV-101 is an autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate for use in B cell-driven autoimmune diseases. KYV-101, specifically targets CD19, a protein expressed on the surface of B cells, which is involved in various types of autoimmune diseases.
Let's personalize your content